DE60111358D1 - 3-(pyrolyllacton)-2-indolinon verbindungen zur verwendung als kinase-hemmstoffe - Google Patents

3-(pyrolyllacton)-2-indolinon verbindungen zur verwendung als kinase-hemmstoffe

Info

Publication number
DE60111358D1
DE60111358D1 DE60111358T DE60111358T DE60111358D1 DE 60111358 D1 DE60111358 D1 DE 60111358D1 DE 60111358 T DE60111358 T DE 60111358T DE 60111358 T DE60111358 T DE 60111358T DE 60111358 D1 DE60111358 D1 DE 60111358D1
Authority
DE
Germany
Prior art keywords
indolinone compounds
lacton
pyrolyl
kinase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60111358T
Other languages
English (en)
Other versions
DE60111358T2 (de
Inventor
Peng Cho Tang
Todd A Miller
Xiaoyuan Li
Ruofei Zhang
Jingrong Cui
Ping Huang
Chung Chen Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Application granted granted Critical
Publication of DE60111358D1 publication Critical patent/DE60111358D1/de
Publication of DE60111358T2 publication Critical patent/DE60111358T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE60111358T 2000-02-28 2001-02-28 3-(pyrolyllacton)-2-indolinon verbindungen zur verwendung als kinase-hemmstoffe Expired - Fee Related DE60111358T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18553600P 2000-02-28 2000-02-28
US185536P 2000-02-28
PCT/US2001/006214 WO2001064681A2 (en) 2000-02-28 2001-02-28 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors

Publications (2)

Publication Number Publication Date
DE60111358D1 true DE60111358D1 (de) 2005-07-14
DE60111358T2 DE60111358T2 (de) 2006-05-11

Family

ID=22681392

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60111358T Expired - Fee Related DE60111358T2 (de) 2000-02-28 2001-02-28 3-(pyrolyllacton)-2-indolinon verbindungen zur verwendung als kinase-hemmstoffe

Country Status (9)

Country Link
US (1) US6465507B2 (de)
EP (1) EP1259514B9 (de)
JP (1) JP2003525296A (de)
AT (1) ATE297395T1 (de)
AU (1) AU2001241798A1 (de)
CA (1) CA2400649A1 (de)
DE (1) DE60111358T2 (de)
ES (1) ES2243461T3 (de)
WO (1) WO2001064681A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316429B1 (en) * 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
US6051593A (en) * 1997-06-20 2000-04-18 Sugen, Inc. 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
DE60021423T2 (de) * 1999-12-21 2006-04-13 Sugen, Inc., San Diego 4-substituierte 7-aza-indolin-2-one und ihre verwendung als proteinkinaseinhibitoren
WO2003000251A1 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel idolinones and uses thereof
ATE468114T1 (de) * 2002-11-08 2010-06-15 High Point Pharmaceuticals Llc Sichere chemische entkuppler zur behandlung von fettsucht
AU2003302665B2 (en) 2002-11-15 2009-12-24 Symphony Evolution, Inc. Kinase modulators
US7157577B2 (en) * 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
US20040266843A1 (en) * 2003-03-07 2004-12-30 Sugen, Inc. Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
US7801585B1 (en) 2003-06-02 2010-09-21 Newlife Sciences Llc System for analyzing and treating abnormality of human and animal tissues
US7640052B2 (en) 2004-05-28 2009-12-29 Ippp, Llc Method of integrated proton beam and therapeutic magnetic resonance therapy
WO2005113561A1 (en) * 2004-05-20 2005-12-01 Sugen, Inc. Cyclicsulfonate pyrrole indolinones as kinase inhibitors
US8108047B2 (en) * 2005-11-08 2012-01-31 Newlife Sciences Llc Device and method for the treatment of pain with electrical energy
CN101007815B (zh) * 2006-01-27 2010-06-23 江苏恒瑞医药股份有限公司 吡咯并六元杂环化合物及其在医药上的用途
WO2007085188A1 (en) 2006-01-27 2007-08-02 Shanghai Hengrui Pharmaceutical Co. Ltd. Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors
CN101054379A (zh) * 2006-04-11 2007-10-17 上海恒瑞医药有限公司 吡咯取代的嘧啶酮衍生物、其制备方法及其在医药上的用途
US20080109049A1 (en) * 2006-11-08 2008-05-08 Schumann Daniel H Device & method for relieving pain
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
WO2008138232A1 (fr) * 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co., Ltd. Dérivés pyrrolo-azotés hétérocycliques, leur préparation et leur utilisation pharmaceutique
WO2008138184A1 (fr) 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co.Ltd. Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
CN101367801B (zh) * 2007-08-15 2011-01-12 上海恒瑞医药有限公司 吡咯并六元n杂环羟基吗啡啉类衍生物的制备方法及其在医药上的应用
CA2736177A1 (en) 2007-09-06 2009-03-12 Boston Biomedical, Inc. Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
US20090149732A1 (en) * 2007-12-08 2009-06-11 Weinstock Ronald J System for use of electrical resonant frequencies in analyzing and treating abnormality of human and animal tissues
US20100324627A1 (en) * 2008-07-28 2010-12-23 Newlife Sciences, Llc Method and apparatus for resistivity measurement, detection and treatment in living tissue
WO2011056985A2 (en) * 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
CN102146082A (zh) * 2010-02-04 2011-08-10 江苏恒瑞医药股份有限公司 吡咯并n杂环类衍生物的可药用的盐、其制备方法及其在医药上的应用
US10085670B2 (en) 2010-11-30 2018-10-02 Newlife Sciences Llc Apparatus and method for treatment of pain with body impedance analyzer
SG11201707418WA (en) 2015-03-13 2017-10-30 Forma Therapeutics Inc Alpha-cinnamide compounds and compositions as hdac8 inhibitors
EP3490553B1 (de) 2016-07-29 2024-08-28 Oncternal Therapeutics, Inc. Kombination mit einer indolinonverbindung und deren verwendung bei der behandlung von lymphomen
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
JP7366031B2 (ja) 2017-09-22 2023-10-20 カイメラ セラピューティクス， インコーポレイテッド タンパク質分解剤およびそれらの使用
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc IRAK joints and used in them
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
EP3817748A4 (de) 2018-07-06 2022-08-24 Kymera Therapeutics, Inc. Tricyclische crbn-liganden und verwendungen davon
MX2021006154A (es) 2018-11-30 2021-08-24 Kymera Therapeutics Inc Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
US11485750B1 (en) 2019-04-05 2022-11-01 Kymera Therapeutics, Inc. STAT degraders and uses thereof
MX2021015378A (es) 2019-06-12 2022-01-24 Truerelief Llc Sistema y metodo para suministrar corriente electrica de impulsos al tejido vivo.
KR20220145325A (ko) 2019-12-17 2022-10-28 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
CN115297931A (zh) 2019-12-23 2022-11-04 凯麦拉医疗公司 Smarca降解剂和其用途
JP2023518423A (ja) 2020-03-19 2023-05-01 カイメラ セラピューティクス， インコーポレイテッド Ｍｄｍ２分解剤およびそれらの使用
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
US11911605B2 (en) 2021-03-05 2024-02-27 Truerelief Llc Method and apparatus for injury treatment
TW202309030A (zh) 2021-05-07 2023-03-01 美商凱麥拉醫療公司 Cdk2降解劑及其用途
AU2023214044A1 (en) 2022-01-31 2024-08-08 Kymera Therapeutics, Inc. Irak degraders and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
ES2064101T3 (es) 1990-04-02 1995-01-16 Pfizer Compuestos de acido bencilfosfonico inhibidores de la quinasa de tirosina.
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
WO1992020642A1 (en) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
JPH06503095A (ja) 1991-05-29 1994-04-07 ファイザー・インコーポレーテッド 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬
AU672224B2 (en) 1992-08-06 1996-09-26 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and whichhave antitumor properties
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US6147106A (en) 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
EP0929520B1 (de) 1996-08-23 2005-11-02 Sugen, Inc. Kombinatorische bibliotheken von indolinone und verwandte produkte und verfahren zur behandlung von krankheiten
US6051593A (en) 1997-06-20 2000-04-18 Sugen, Inc. 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
US6133305A (en) 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine

Also Published As

Publication number Publication date
CA2400649A1 (en) 2001-09-07
US20020042427A1 (en) 2002-04-11
EP1259514B1 (de) 2005-06-08
ATE297395T1 (de) 2005-06-15
US6465507B2 (en) 2002-10-15
JP2003525296A (ja) 2003-08-26
DE60111358T2 (de) 2006-05-11
ES2243461T3 (es) 2005-12-01
WO2001064681A3 (en) 2002-04-18
WO2001064681A2 (en) 2001-09-07
EP1259514A2 (de) 2002-11-27
AU2001241798A1 (en) 2001-09-12
EP1259514B9 (de) 2005-11-09

Similar Documents

Publication Publication Date Title
DE60111358D1 (de) 3-(pyrolyllacton)-2-indolinon verbindungen zur verwendung als kinase-hemmstoffe
WO1999048868A3 (en) Heterocyclic classes of compounds for the modulating tyrosine protein kinase
NO20035226D0 (no) Templatinkluderende molekyler og fremgangsmåter til anvendelse av slike molekyler
DK1525200T3 (da) 2-(3-aminoaryl)amino-4-aryl-thiazoler til sygdomsbehandling
NO20070907L (no) Pyrrolo-pyridin kinase modulatorer
EA200001102A1 (ru) Способ синтеза ингибиторов сох-2 (циклооксигеназы-2)
CY1109760T1 (el) Παραγωγα ινδολης-3-θειου
ATE301661T1 (de) Makroheterocyclische verbindungen als kinase inhibitoren
CY1111884T1 (el) Μονοκλωνικο αντισωμα αντι-met, θραυσματα και κομιστες αυτου, για την αγωγη νεοπλασιων και αντιστοιχα προϊοντα
ATE354568T1 (de) Nicht-imidazol aryloxypiperidine als h3 rezeptor liganden
DK1353917T3 (da) Ny fremgangsmåde til syntesen af 5-(4-fluorphenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrol-3-carboxylsyre phenylamid
DE60007267D1 (de) 4,5-diaryl-3(2h)-furanon derivate als cyclooxygenase-2 inhibitoren
ATE419253T1 (de) Inhibitoren von thienopyridin- und furopyridinkinase
BRPI0414541B8 (pt) compostos heterocíclicos fundidos tendo atividade de modulação de receptor de serotonina, método de preparação de compostos intermediários
DE60014670D1 (de) Antipicornavirale verbindungen und zusammensetzungen, ihre pharmazeutische verwendung, und materialien für ihre synthese
EP1610678A4 (de) Antikörper und diese enthaltende pharmazeutische zusammensetzungen zur hemmung der aktivität von metalloproteinen
ATE253930T1 (de) Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)- aktivierungsweges
PT975588E (pt) Compostos antipicornavirais, composicoes que os contem e metodos para a sua utilizacao
ATE295724T1 (de) Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse
DK1355152T3 (da) Fremgangsmåde til at identificere en forbindelse til modulering af wnt-signalkaskaden
DE502004009136D1 (de) NEUE HETEROARYLSUBSTITUIERTE ACETONDERIVATE ALS HEMMSTOFFE DER PHOSPHOLIPASE A sb 2 /sb
ATE365035T1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
ATE308513T1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
DE50308230D1 (de) Pyrazoloisoquinolinenderivaten zur inhibierung von nfkappab-induzierende kinase
DE50214750D1 (de) Kinase inhibitoren und deren verwendung

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: SUGEN, INC., SAN DIEGO, CALIF., US

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee